Natco Pharma (NATCOPHARM.NS) Stock Price
Natco Pharma Price
Over the last 19 years Natco Pharma grew revenue by 16.0% annually, reaching 40.78 B INR. Earnings per share have grown at 22.4% per year over the last 19 years. For Natco Pharma, the net margin of 34.8% is up versus 8.7% a few years ago. At today's price the dividend yield works out to roughly 0.64%. The payout ratio is around 12% of earnings. The dividend has grown at 17.1% per year over the past 19 years. The consensus 12-month price target for Natco Pharma is 930.75 INR, about 18.7% above where the stock trades today. Of 16 analysts, 3 rate the stock a buy — an overall Sell consensus.
Natco Pharma stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Natco Pharma business model & stock analysis
Frequently asked questions about Natco Pharma
Natco Pharma Ltd is an Indian pharmaceutical company with a well-defined business model. The company primarily focuses on the development, manufacturing, and marketing of a wide range of generic pharmaceutical products. It has a strong presence in both domestic and international markets, supplying affordable and high-quality medicines. Natco Pharma follows a vertically integrated business approach, encompassing the entire pharmaceutical value chain, including R&D, API manufacturing, formulation development, and marketing. By consistently delivering innovative pharmaceutical solutions, Natco Pharma aims to fulfill the healthcare needs of patients worldwide while ensuring sustainable growth and profitability.
Natco Pharma Ltd is primarily active in the pharmaceutical industry.
The main competitors of Natco Pharma Ltd in the market include Sun Pharmaceutical Industries Ltd, Dr. Reddy's Laboratories Ltd, Lupin Limited, Cipla Limited, and Glenmark Pharmaceuticals Ltd.
Natco Pharma Ltd is an Indian pharmaceutical company with a rich history and background. Founded in 1981, the company has emerged as a leading player in the global pharmaceutical industry. Natco Pharma specializes in developing, manufacturing, and marketing generic pharmaceuticals, active pharmaceutical ingredients (APIs), and biologics. With a strong focus on research and development, the company has a diverse product portfolio across multiple therapeutic areas, including oncology, cardiology, gastroenterology, and more. Natco Pharma Ltd is known for its commitment to quality, affordability, and accessibility of healthcare products, making it a trusted name in the pharmaceutical sector.
Natco Pharma Ltd has achieved several significant milestones over the years. Firstly, the company received approval for its first ANDA from the US FDA in 2003, marking a major breakthrough in its international presence. In 2012, Natco Pharma Ltd entered into a landmark agreement with a leading pharmaceutical company to manufacture and market a generic version of a widely prescribed anticancer drug, showcasing its expertise in the oncology segment. Furthermore, the company has filed multiple Abbreviated New Drug Applications (ANDAs) and received several approvals, strengthening its product portfolio. With its consistent focus on innovation, quality, and expanding global reach, Natco Pharma Ltd continues to achieve remarkable milestones in the pharmaceutical industry.
Natco Pharma Ltd is primarily present in multiple countries and regions worldwide. With a strong global footprint, the company operates across countries like the United States, Canada, Europe, Australia, South Africa, and various Asian countries. Natco Pharma Ltd has established a significant presence in these markets, leveraging its expertise in pharmaceutical research, development, and marketing. With its continuous efforts towards expanding its international operations, the company aims to serve diverse patient populations and healthcare needs globally.
The values and corporate philosophy of Natco Pharma Ltd are centered around innovation, excellence, and ethical business practices. Natco Pharma is committed to providing high-quality pharmaceutical products and services that improve the health and well-being of individuals. The company is known for its dedication to research and development, striving to develop cutting-edge medicines and therapies that address unmet medical needs. Natco Pharma also prioritizes sustainability and social responsibility, aiming to contribute positively to society and the environment. With their strong emphasis on integrity and customer satisfaction, Natco Pharma Ltd continues to establish itself as a trusted and reliable player in the pharmaceutical industry.
Analysts currently set an average price target of 924.22 INR for the Natco Pharma stock (median: 930.75 INR), implying +17.9 % versus the latest price. The consensus is based on 16 analyst ratings.
16 analysts currently rate the Natco Pharma stock: 3 recommend buying, 4 holding and 9 selling.
Converted at the current exchange rate, the Natco Pharma share trades at 7.38 EUR (784.00 INR).
The Natco Pharma share (NATCOPHARM.NS) is listed on 2 stock exchanges, including: NSE (Indien) (NATCOPHARM.NS).
Natco Pharma Ltd is a multinational company specializing in the development, manufacturing, and marketing of medications. With its headquarters in Hyderabad, India, they distribute their products worldwide in over 40 countries and continue to grow. The company operates in various sectors, including oncology products, active pharmaceutical ingredients (API), nucleosides, generics, and bioequivalents. Oncology products are their main sector, where Natco holds a significant market position. Through intensive research and development, Natco Pharma has developed a variety of medications to provide necessary protection and treatment for cancer patients. In addition, Natco has developed a wide range of API products. With over 200 APIs, Natco is one of the leading companies in India in this field. Production also includes more than 70 generic medications developed as cost-effective solutions for the treatment of various diseases. Another business area is the production of nucleosides, which are a group of organic compounds involved in the formation of nucleic acids in the human body. These products are used in HIV treatment. Furthermore, Natco Pharma also offers bioequivalents. These products are developed and manufactured in the same way as the original product and have the same efficacy and safety. Bioequivalents often replace expensive original products, resulting in cost savings for patients. Overall, Natco Pharma's business model is designed for self-sustainability. This means that they are self-funded and operate independently from other investors. The products are very affordable while maintaining a high quality standard. Through global distribution, Natco becomes an important company in many areas of medicine. The financial structure of the company is based on a broad revenue base. This means that the company does not rely on a single product but instead offers multiple products in different markets. This minimizes risk and provides more solid and reliable revenue forecasts. Additionally, Natco has a portfolio of affordable and effective bioequivalents and generics. This has given the company a significant market position in many countries. The company emphasizes strong and independent production, allowing for flexibility in product and service offerings. As a whole, the company's concept is focused on diversity. Through its strong presence in cancer-related products and generic alternatives, Natco Pharma Ltd has strengthened its global standing. The company also relies on its research and development department, which constantly works on new products.
The revenue of Natco Pharma is 40.78 B INR. This figure is based on current financial data and reflects the company's business performance.
The profit of Natco Pharma is 14.19 B INR. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Natco Pharma is currently 9.90. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Natco Pharma stock.
The price-to-sales ratio (P/S) of Natco Pharma is currently 3.44. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Natco Pharma stock.
The Eulerpool Quality Score for Natco Pharma is 7/10.
The ISIN of Natco Pharma is INE987B01026. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of Natco Pharma is NATCOPHARM.NS. The ticker symbol is used to trade Natco Pharma shares on the stock exchange.
Natco Pharma stock
Natco Pharma Peer Group
Natco Pharma Ticker
Natco Pharma FIGI
All fundamentals and in-depth analysis of Natco Pharma
Our stock analysis for Natco Pharma stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Natco Pharma. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.